ArticleFrontiers in artificial intelligence2026
Hybrid machine learning forecasting for resilient and sustainable pharmaceutical supply chains under regulatory and seasonal disruption.
Article in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Demand forecasting in pharmaceutical supply chains is not a simple task. In regulated markets it becomes more difficult, because seasonality, epidemic waves, and also policy changes can make demand behavior unstable. This study proposes a hybrid residual learning approach for forecasting pharmaceutical demand in Türkiye. Methods: The model uses Support Vector Regression (SVR) together with Deep Neural Networks (DNN). In this structure, SVR estimates the main or baseline part of demand, and DNN tries to learn the remaining nonlinear residual variation. The framework was tested with real ERP-based demand data, including 10 critical pharmaceutical products in a 24-month period. For evaluation, temporal holdout testing was used. The model was also compared with ARIMA, Prophet, Random Forest, XGBoost, and LSTM. Statistical validation was done by paired t-tests and Diebold-Mariano tests. Results: The proposed SVR-DNN framework performed better than the standalone SVR and DNN models. It also stayed as the strongest model when it was compared with the wider benchmark models. The hybrid model gave the lowest forecasting errors, and it showed the highest explanatory performance among the tested models. Discussion: The results show that when baseline demand estimation is separated from residual correction, forecasting performance can be improved in pharmaceutical demand conditions that are sensitive to disruptions. SHAP analysis also helped the interpretation of model, because it showed the main factors that affect demand variation. The proposed framework gives an interpretable and context-aware forecasting model for pharmaceutical supply chains working under regulatory and seasonal disruption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.